메뉴 건너뛰기




Volumn 32, Issue 7, 2009, Pages 431-439

Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer

Author keywords

Bevacizumab; Chemotherapy; Efficacy; Metastatic colorectal cancer; Oxaliplatin; Safety

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MATUZUMAB; OXALIPLATIN; PANITUMUMAB; TEGAFUR; URACIL;

EID: 68149165603     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218354     Document Type: Review
Times cited : (5)

References (58)
  • 1
    • 4644252335 scopus 로고    scopus 로고
    • Meta-Analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis
    • Thirion P, Michiels S, Pignon JP, Buyse M, Braud AC, Carlson RW, O'Connell M, Sargent P, Piedbois P; Meta-Analysis Group in Cancer: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766-3775.
    • (2004) J Clin Oncol , vol.22 , pp. 3766-3775
    • Thirion, P.1    Michiels, S.2    Pignon, J.P.3    Buyse, M.4    Braud, A.C.5    Carlson, R.W.6    O'Connell, M.7    Sargent, P.8    Piedbois, P.9
  • 6
    • 1842569206 scopus 로고    scopus 로고
    • A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    • Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
    • (2004) J Clin Oncol , vol.22 , pp. 23-30
    • Goldberg, R.M.1    Sargent, D.J.2    Morton, R.F.3    Fuchs, C.S.4    Ramanathan, R.K.5    Williamson, S.K.6    Findlay, B.P.7    Pitot, H.C.8    Alberts, S.R.9
  • 8
    • 24644457747 scopus 로고    scopus 로고
    • Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartení G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
    • Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartení G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C; Gruppo Oncologico Dell'Italia Meridionale: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 2005;23:4866-4875.
  • 9
    • 24644432555 scopus 로고    scopus 로고
    • Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B; European Organisation for Research and Treatment of Cancer Gastrointestinal Group: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-4865.
    • Köhne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, Lorenz M, Reichardt P, Rückle-Lanz H, Frickhofen N, Fuchs R, Mergenthaler HG, Langenbuch T, Vanhoefer U, Rougier P, Voigtmann R, Müller L, Genicot B, Anak O, Nordlinger B; European Organisation for Research and Treatment of Cancer Gastrointestinal Group: Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-4865.
  • 10
    • 0037531121 scopus 로고    scopus 로고
    • Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
    • Rothenberg M, Oza A, Bigelow R, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003;21:2059-2069.
    • (2003) J Clin Oncol , vol.21 , pp. 2059-2069
    • Rothenberg, M.1    Oza, A.2    Bigelow, R.3    Berlin, J.D.4    Marshall, J.L.5    Ramanathan, R.K.6    Hart, L.L.7    Gupta, S.8    Garay, C.A.9    Burger, B.G.10    Le Bail, N.11    Haller, D.G.12
  • 12
    • 34447255724 scopus 로고    scopus 로고
    • FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
    • Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffiths GO, Parmar MK, Stephens RJ; FOCUS Trial Investigators; National Cancer Research Institute Colorectal Clinical Studies Group: Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143-152.
    • (2007) Lancet , vol.370 , pp. 143-152
    • Seymour, M.T.1    Maughan, T.S.2    Ledermann, J.A.3    Topham, C.4    James, R.5    Gwyther, S.J.6    Smith, D.B.7    Shepherd, S.8    Maraveyas, A.9    Ferry, D.R.10    Meade, A.M.11    Thompson, L.12    Griffiths, G.O.13    Parmar, M.K.14    Stephens, R.J.15
  • 13
    • 68149169601 scopus 로고    scopus 로고
    • Berry S, Van Cutsem E, Kretzschmar A, Michael M, Rivera F, DiBartolomeo M, Mazier MA, Andre N, Cunningham D: Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 2008 (meet abstr);26:4025.
    • Berry S, Van Cutsem E, Kretzschmar A, Michael M, Rivera F, DiBartolomeo M, Mazier MA, Andre N, Cunningham D: Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. J Clin Oncol 2008 (meet abstr);26:4025.
  • 15
    • 2142703727 scopus 로고    scopus 로고
    • Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    • Grothey A, Sargent D, Goldberg RM, Schmoll HJ: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214.
    • (2004) J Clin Oncol , vol.22 , pp. 1209-1214
    • Grothey, A.1    Sargent, D.2    Goldberg, R.M.3    Schmoll, H.J.4
  • 17
    • 68149182241 scopus 로고    scopus 로고
    • accessed 2 November 2008
    • Erbitux™ prescribing information. www.fda.gov/cder/foi/label/ 2004/125084lbl.pdf (accessed 2 November 2008).
    • Erbitux™ prescribing information
  • 18
    • 84976585919 scopus 로고    scopus 로고
    • accessed 2 November 2008
    • Erbitux summary of product characteristics. www.emea.europa.eu/ humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdf (accessed 2 November 2008).
    • Erbitux summary of product characteristics
  • 22
    • 33750373924 scopus 로고    scopus 로고
    • Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer
    • Ellis LM: Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 2000;33(suppl 10):S1-S7.
    • (2000) Semin Oncol , vol.33 , Issue.SUPPL. 10
    • Ellis, L.M.1
  • 24
    • 20544471876 scopus 로고    scopus 로고
    • Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
    • Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-3712.
    • (2005) J Clin Oncol , vol.23 , pp. 3706-3712
    • Kabbinavar, F.F.1    Hambleton, J.2    Mass, R.D.3    Hurwitz, H.I.4    Bergsland, E.5    Sarkar, S.6
  • 27
    • 34248173883 scopus 로고    scopus 로고
    • Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd; Eastern Cooperative Oncology Group Study E3200: Bevacizumab in combination with oxaliplatin, fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol 2007;25:1539-1544.
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    O'Dwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson 3rd, A.B.8
  • 28
    • 68149162193 scopus 로고    scopus 로고
    • Reinacher-Schick A, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capeci-tabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008 (meet abstr);26:4030.
    • Reinacher-Schick A, Kubicka S, Freier W, Arnold D, Dietrich G, Geissler M, Hegewisch-Becker S, Graeven U, Schmoll H, Schmiegel W: Activity of the combination of bevacizumab (Bev) with capeci-tabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): a randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604). J Clin Oncol 2008 (meet abstr);26:4030.
  • 29
    • 0037208589 scopus 로고    scopus 로고
    • Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer
    • Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
    • (2003) J Clin Oncol , vol.21 , pp. 60-65
    • Kabbinavar, F.1    Hurwitz, H.I.2    Fehrenbacher, L.3    Meropol, N.J.4    Novotny, W.F.5    Lieberman, G.6    Griffing, S.7    Bergsland, E.8
  • 30
  • 31
    • 68149159734 scopus 로고    scopus 로고
    • Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Cassidy J: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(18S):4028.
    • Saltz L, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T, Cassidy J: Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/ NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. J Clin Oncol 2007;25(18S):4028.
  • 32
    • 34748918351 scopus 로고    scopus 로고
    • Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis
    • Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP: Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007;8:898-911.
    • (2007) Lancet Oncol , vol.8 , pp. 898-911
    • Golfinopoulos, V.1    Salanti, G.2    Pavlidis, N.3    Ioannidis, J.P.4
  • 33
    • 53549126631 scopus 로고    scopus 로고
    • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk
    • Kabbinavar F, Irl C, Zurlo A, Hurwitz, H: Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. Oncology 2008;75:215-23.
    • (2008) Oncology , vol.75 , pp. 215-223
    • Kabbinavar, F.1    Irl, C.2    Zurlo, A.3    Hurwitz, H.4
  • 34
    • 58249088835 scopus 로고    scopus 로고
    • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials
    • Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O: Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205.
    • (2009) J Clin Oncol , vol.27 , pp. 199-205
    • Kabbinavar, F.F.1    Hurwitz, H.I.2    Yi, J.3    Sarkar, S.4    Rosen, O.5
  • 35
    • 68149098458 scopus 로고    scopus 로고
    • Kozloff MF, Sugrue MM, Purdie DM, Berlin JD, Flynn PJ, Kabbinavar FF, Sargent DJ, Dong W, Grothey A: Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients (pts) with metastatic CRC: results from the BRiTE observational cohort study. J Clin Oncol 2008 (meet abstr);26:4026.
    • Kozloff MF, Sugrue MM, Purdie DM, Berlin JD, Flynn PJ, Kabbinavar FF, Sargent DJ, Dong W, Grothey A: Safety and effectiveness of bevacizumab (BV) plus chemotherapy (CT) in elderly patients (pts) with metastatic CRC: results from the BRiTE observational cohort study. J Clin Oncol 2008 (meet abstr);26:4026.
  • 36
    • 68149158805 scopus 로고    scopus 로고
    • Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Bergstrom B, Gilberg F, Saltz L: XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (mCRC): updated survival and tolerability results. Presented at: 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Fransisco, CA (meet abstr):382. www.asco.org.
    • Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Bergstrom B, Gilberg F, Saltz L: XELOX-1/NO16966, a randomized phase III trial of first-line XELOX compared with FOLFOX4 for patients with metastatic colorectal cancer (mCRC): updated survival and tolerability results. Presented at: 2009 Gastrointestinal Cancers Symposium, 15-17 January 2009, San Fransisco, CA (meet abstr):382. www.asco.org.
  • 37
    • 68149150404 scopus 로고    scopus 로고
    • Bendell JC, Fernando N, Morse M, Blobe G, Yu D, Sutton L, Schaffer S, Honeycutt W, Franklin A, Hurwitz H: A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. J Clin Oncol 2006 (meet abstr);24:3541.
    • Bendell JC, Fernando N, Morse M, Blobe G, Yu D, Sutton L, Schaffer S, Honeycutt W, Franklin A, Hurwitz H: A phase II study of oxaliplatin (OX), capecitabine (CAP), and bevacizumab (BV) in the treatment of metastatic colorectal cancer. J Clin Oncol 2006 (meet abstr);24:3541.
  • 39
    • 56749169353 scopus 로고    scopus 로고
    • Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)
    • Grothey A, Sugrue M, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-5334.
    • (2008) J Clin Oncol , vol.26 , pp. 5326-5334
    • Grothey, A.1    Sugrue, M.2    Purdie, D.M.3    Dong, W.4    Sargent, D.5    Hedrick, E.6    Kozloff, M.7
  • 40
    • 68149101350 scopus 로고    scopus 로고
    • Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Kozloff MF, Dong W, Sugrue MM: The safety of long-term bevacizumab use: results from the BRiTE observational cohort study (OCS). J Clin Oncol 2008 (meet abstr);26:4103.
    • Purdie DM, Berlin JD, Flynn PJ, Grothey A, Kabbinavar FF, Kozloff MF, Dong W, Sugrue MM: The safety of long-term bevacizumab use: results from the BRiTE observational cohort study (OCS). J Clin Oncol 2008 (meet abstr);26:4103.
  • 41
    • 68149179220 scopus 로고    scopus 로고
    • Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn PJ, Dong W, Suzuki S, Sarkar S, Sugrue MM, Grothey A: Management of hypertension in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy. Presented at: 2007 Gastrointestinal Cancers Symposium, 19-21 January 2007, Orlando, FL (meet abstr):364. www.asco.org.
    • Kozloff M, Hainsworth J, Badarinath S, Cohn A, Flynn PJ, Dong W, Suzuki S, Sarkar S, Sugrue MM, Grothey A: Management of hypertension in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy. Presented at: 2007 Gastrointestinal Cancers Symposium, 19-21 January 2007, Orlando, FL (meet abstr):364. www.asco.org.
  • 42
    • 68149126034 scopus 로고    scopus 로고
    • Labianca R, Floriani I, Cortesi E, Isa L, Zaniboni A, Marangolo M, Frontini L, Barni S, Beretta GD, Sobrero A, Italian Group for the Study of Digestive Tract Cancer: Alternating versus continuous 'FOLFIRI' in advanced colorectal cancer (ACC): a randomized 'GISCAD' trial. J Clin Oncol 2007 (meet abstr);24:3505.
    • Labianca R, Floriani I, Cortesi E, Isa L, Zaniboni A, Marangolo M, Frontini L, Barni S, Beretta GD, Sobrero A, Italian Group for the Study of Digestive Tract Cancer: Alternating versus continuous 'FOLFIRI' in advanced colorectal cancer (ACC): a randomized 'GISCAD' trial. J Clin Oncol 2007 (meet abstr);24:3505.
  • 44
    • 68149100369 scopus 로고    scopus 로고
    • Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Louvet C, de Gramont A: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol 2007 (meet abstr);25:4013.
    • Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Louvet C, de Gramont A: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study. J Clin Oncol 2007 (meet abstr);25:4013.
  • 45
    • 34548544244 scopus 로고    scopus 로고
    • Use of calcium and magnesium salts to reduce oxaliplatin-relat-ed neurotoxicity
    • Hochster HS, Grothey A, Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-relat-ed neurotoxicity. J Clin Oncol 2007;25:4028-4029.
    • (2007) J Clin Oncol , vol.25 , pp. 4028-4029
    • Hochster, H.S.1    Grothey, A.2    Childs, B.H.3
  • 46
    • 68149124092 scopus 로고    scopus 로고
    • Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS: Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008 (meet abstr);26:4010.
    • Grothey A, Hart LL, Rowland KM, Ansari RH, Alberts SR, Chowhan NM, Shpilsky A, Hochster HS: Intermittent oxaliplatin (oxali) administration and time-to-treatment-failure (TTF) in metastatic colorectal cancer (mCRC): final results of the phase III CONcePT trial. J Clin Oncol 2008 (meet abstr);26:4010.
  • 47
    • 0028935608 scopus 로고
    • Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
    • Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-1797.
    • (1995) J Clin Invest , vol.95 , pp. 1789-1797
    • Warren, R.S.1    Yuan, H.2    Matli, M.R.3    Gillett, N.A.4    Ferrara, N.5
  • 48
    • 11144354392 scopus 로고    scopus 로고
    • Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    • Willett CG, Boucher Y, Di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
    • (2004) Nat Med , vol.10 , pp. 145-147
    • Willett, C.G.1    Boucher, Y.2    Di Tomaso, E.3
  • 49
    • 0029949160 scopus 로고    scopus 로고
    • Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
    • Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U.S.A.1996;93:14765-14770.
    • (1996) Proc Natl Acad Sci U.S.A , vol.93 , pp. 14765-14770
    • Yuan, F.1    Chen, Y.2    Dellian, M.3    Safabakhsh, N.4    Ferrara, N.5    Jain, R.K.6
  • 50
    • 0034306974 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions
    • Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al.: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-5570.
    • (2000) Cancer Res , vol.60 , pp. 5565-5570
    • Lee, C.G.1    Heijn, M.2    di Tomaso, E.3    Griffon-Etienne, G.4    Ancukiewicz, M.5    Koike, C.6
  • 51
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000;14;407:249-257.
    • (2000) Nature , vol.14 , Issue.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 52
    • 54249108586 scopus 로고    scopus 로고
    • Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer
    • meet abstr 4006, :179s
    • Allegra CJ, Yothers G, O'Connell MJ, et al.: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer. J Clin Oncol 2008;26(suppl):179s (meet abstr 4006).
    • (2008) J Clin Oncol , vol.26 , Issue.SUPPL.
    • Allegra, C.J.1    Yothers, G.2    O'Connell, M.J.3
  • 53
    • 42949130734 scopus 로고    scopus 로고
    • Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    • Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T: Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26: 1830-1835.
    • (2008) J Clin Oncol , vol.26 , pp. 1830-1835
    • Gruenberger, B.1    Tamandl, D.2    Schueller, J.3    Scheithauer, W.4    Zielinski, C.5    Herbst, F.6    Gruenberger, T.7
  • 54
    • 0037837645 scopus 로고    scopus 로고
    • Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
    • Scheithauer W, Kornek GV, Raderer M, et al.: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307-1312.
    • (2003) J Clin Oncol , vol.21 , pp. 1307-1312
    • Scheithauer, W.1    Kornek, G.V.2    Raderer, M.3
  • 55
    • 68149158806 scopus 로고    scopus 로고
    • Van Cutsem E, Berry SR, Michael M, Kretzschmar A, Rivera F, DiBartolomeo M, Mazier M, Andre N, Cunningham D: Safety and efficacy of bevacizumab plus standard first-line chemotherapy in patients with metastatic colorectal cancer: First BEAT. Ann Oncol 2008 (meet abstr):19:357P.
    • Van Cutsem E, Berry SR, Michael M, Kretzschmar A, Rivera F, DiBartolomeo M, Mazier M, Andre N, Cunningham D: Safety and efficacy of bevacizumab plus standard first-line chemotherapy in patients with metastatic colorectal cancer: First BEAT. Ann Oncol 2008 (meet abstr):19:357P.
  • 56
    • 68149155951 scopus 로고    scopus 로고
    • Cassidy J, Cunningham D, S. Berry S, Rivera F, Clarke S, Kretzschmar A, Diaz-Rubio E, Van Cutsem E, Saltz L: Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol 2008 (meet abstr):26:4022.
    • Cassidy J, Cunningham D, S. Berry S, Rivera F, Clarke S, Kretzschmar A, Diaz-Rubio E, Van Cutsem E, Saltz L: Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) + bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966. J Clin Oncol 2008 (meet abstr):26:4022.
  • 57
    • 68149158752 scopus 로고    scopus 로고
    • Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW: Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer liver metastases. Presented at: 2007 Gastrointestinal Cancers Symposium, 19-21 January 2007, Orlando, FL (meet abstr):234. www.asco.org.
    • Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey J, Rodriguez-Bigas MA, Curley SA, Feig BW: Complication rates following hepatic surgery in patients receiving neoadjuvant bevacizumab for colorectal cancer liver metastases. Presented at: 2007 Gastrointestinal Cancers Symposium, 19-21 January 2007, Orlando, FL (meet abstr):234. www.asco.org.
  • 58
    • 37048998995 scopus 로고    scopus 로고
    • Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases
    • Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, Chang DZ, Curley SA, Abdalla EK, Ellis LM, Vauthey JN: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110:2761-2767.
    • (2007) Cancer , vol.110 , pp. 2761-2767
    • Ribero, D.1    Wang, H.2    Donadon, M.3    Zorzi, D.4    Thomas, M.B.5    Eng, C.6    Chang, D.Z.7    Curley, S.A.8    Abdalla, E.K.9    Ellis, L.M.10    Vauthey, J.N.11


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.